制药公司2020_未来发展蓝图（英文版）_19页_954kb

Summary of McCANN: HEALTH: PHARMA 2020 – From Vision to Decision

Core Content

The document outlines the evolving landscape of the pharmaceutical industry in the context of a rapidly changing global health environment. It highlights the challenges and opportunities facing pharma companies, particularly in the wake of shifting market demands, regulatory pressures, and technological advancements.

Main Viewpoints

• Changing Market Demands: Consumers and payers are increasingly demanding value-based healthcare, defined by both clinical outcomes and cost-effectiveness. This shift is pushing pharma companies to move away from traditional blockbuster models and high pricing strategies.

• Impact of Generics and Price Controls: Generic competition is expected to cut pharma revenues by $148 billion between 2012 and 2018. Developed markets like the EU and Japan are also implementing or expanding generic policies, further pressuring industry profitability.

• Healthcare as a Human Right: The trend towards universal care and the principle of healthcare as a human right is reshaping the industry. The Affordable Care Act (ACA) in the US is projected to reduce branded medicine revenue by $112 billion over the next decade.

• Corporate Stagnation and Innovation Challenges: Pharma companies are struggling with outdated R&D strategies, poor portfolio management, and a lack of incentives for innovation. The industry has shifted from an "fail early, fail cheap" culture to one where "failing late, failing more, and failing expensively" is the norm.

• Opportunities in Personalized and Preventive Care: The rise of personalized and preventive medicine, driven by genetics and genomic research, presents significant opportunities. These approaches focus on individualized treatment and early disease management.

• Emerging Markets Growth: Expenditures on medicines in growth markets are expected to nearly double from $205 billion in 2011 to $499 billion by 2020. Pharma companies are adopting diverse strategies, such as Roche's high-value innovation model and GSK's focus on generics and differential pricing.

• mHealth and "Pill Plus" Solutions: Mobile health (mHealth) and integrated solutions combining drugs with digital tools (e.g., mobile apps, monitoring systems) are gaining traction. These innovations aim to improve compliance, reach remote communities, and shift care from hospitals to home environments.

• Collaboration and Specialization: The industry is increasingly recognizing the value of open innovation and collaboration with academia, governments, and other private-sector entities. Specialization is becoming essential for success, with examples like Pfizer's focus on vascular health and GSK's on oncology.

Key Information

• Regulatory and Market Pressures: Governments and payers are moving towards value-based purchasing and pay-for-performance models, which require pharma companies to provide robust evidence of clinical and economic value.

• HONDAs as a Focus Area: Hypertensive, Obese, Non-compliant, and Diabetic Asthmatics (HONDAs) account for an estimated 70% of healthcare costs. Addressing these conditions through home-based and patient-centered care is both a challenge and an opportunity.

• Genomics and Data-Driven Medicine: Advances in genetics are enabling more targeted treatments. However, pharma companies have historically underinvested in genomics, spending only 7% of their R&D budgets in 2011. This share is expected to rise to over 20% by 2020.

• Technology Integration: mHealth and digital tools are playing a growing role in healthcare delivery. Examples include mobile apps for disease management, digital pills, and innovative distribution methods like Colalife’s use of coke bottles for drug delivery in rural areas.

• Need for Better Communication: Pharma companies must improve their communication with payers and decision-makers, providing compelling data and evidence that demonstrate real-world impact and patient experience.

• Portfolio Pruning and Focus: Companies are advised to prune their portfolios and focus on specialized areas to enhance innovation and efficiency.

Opportunities

• Personalized Medicine: Tailoring treatments to individual genetic profiles and comorbid conditions is a major opportunity.
• Preventive Care: Emphasizing early detection and prevention can reduce long-term healthcare costs and improve patient outcomes.
• Collaborative R&D: Partnerships across sectors are becoming more common, especially for pre-competitive research and shared data.
• Emerging Markets: These markets offer substantial growth potential, though business models must be tailored to local conditions and regulations.

Conclusion

The pharmaceutical industry is at a crossroads, facing significant challenges due to regulatory and market pressures but also uncovering substantial opportunities through innovation, collaboration, and a shift towards personalized, preventive, and data-driven care. Success will depend on adapting corporate culture, focusing on specialization, and effectively communicating value to all stakeholders.